Printer Friendly

Zai Lab announces completion of ZL-2306 study for ovarian cancer patients.

Zai Lab announced the early completion of an open-label study to evaluate the pharmacokinetic, or PK, profile of ZL-2306 made in China in Chinese ovarian cancer patients. The study demonstrated comparable PK profile of Chinese patients who were administered ZL-2306 to the PK profile of patients evaluated in Tesaro's clinical trials using product manufactured outside of China. These results are important in supporting the regulatory review of ZL-2306, a potent and highly selective PARP1/2 inhibitor, in ovarian cancer patients in mainland China. The open-label PK Study enrolled 36 subjects with dose levels ranging from 100mg, 200mg and 300mg, and assessed the PK profile of ZL-2306 made in China. The objective was to evaluate ZL-2306's PK profile and tolerability in Chinese patients, and to compare the key PK parameters with global data. The results showed that the drug exposure increased proportionally from 100mg to 300mg, with no unexpected safety issues noted. All key PK parameters were comparable to those in global studies. The population PK data and analysis showed no ethnicity differences between Chinese and non-Chinese patients.

COPYRIGHT 2018 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Geographic Code:9CHIN
Date:Aug 20, 2018
Words:177
Previous Article:SL Green Realty agrees to sell interest in 3 Columbus Circle.
Next Article:SemGroup to sell 49% interest in Maurepas Pipeline for $350M.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters